Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 8006-8006 ◽  
Author(s):  
David Planchard ◽  
Harry J.M. Groen ◽  
Tae Min Kim ◽  
James R. Rigas ◽  
Pierre Jean Souquet ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Study ◽  
Braf Inhibitor ◽  
Mek Inhibitor ◽  
Small Cell ◽  
Braf V600e ◽  
Small Cell Lung

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

2010 ◽  
Vol 16 (8) ◽  
pp. 2450-2457 ◽  
Author(s):  
Eric B. Haura ◽  
Alejandro D. Ricart ◽  
Timothy G. Larson ◽  
Philip J. Stella ◽  
Lyudmila Bazhenova ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Study ◽  
Mek Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Previously Treated Patients ◽  
Previously Treated

A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer

Lung Cancer ◽  
2006 ◽  
Vol 54 (1) ◽  
pp. 57-62 ◽  
Author(s):  
Jung Han Kim ◽  
Dong Hun Lee ◽  
Hyun Chun Shin ◽  
Jung Hye Kwon ◽  
Joo Young Jung ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Study ◽  
Small Cell ◽  
Small Cell Lung ◽  
Split Dose
Sign in / Sign up

Export Citation Format

Share Document